BeiGene

Our investigational Bruton’s tyrosine kinase (BTK) targeting chimeric degradation activation compound (CDAC), BGB-16673, was recently granted Fast Track Designation by the FDA for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma #CLL/#SLL, acknowledging its potential to address significant unmet need. Learn more: https://lnkd.in/eUcUEHGS

At BeiGene, we are driven by the power of change. Our Be the Change program reflects this commitment by offering a global volunteer time-off policy, giving colleagues a full day of paid time off each year to volunteer.     Hear from one of our dedicated changemakers, Lisa Porat, who has passionately volunteered for over a decade. Learn what volunteering means to her and why she’s committed about giving back.     Discover more about our culture of volunteerism in our Responsible Business & Sustainability Report: https://bit.ly/3QTIRs3.

This summer, we welcomed 51 interns across the United States and Europe, including a group of 16 who joined us onsite at our new U.S. manufacturing and clinical R&D facility in Hopewell, N.J. We deeply appreciate their valuable contributions and hard work. Thank you all for helping us advance our mission to deliver impactful medicines to more people around the world. We look forward to seeing you all achieve your goals!      Learn more about working at BeiGene at https://bit.ly/3yQzp2l. #internship 

We believe no one should navigate the emotional and physical challenges of a cancer diagnosis alone. Sharing and learning from each other's stories is a powerful way to communicate, connect, and heal.     We’re thankful for patients like Anna, who bravely share their experiences, offering hope, encouragement, and empowerment to others. Together, we build a strong community of voices united against cancer. Explore more of Anna’s full story here: https://lnkd.in/erNBQEfA.  #PatientsFirst #CLL

Each year, The Galien Foundation recognizes the leading-edge of scientific advances in life sciences and we are honored our BTK inhibitor was nominated as a "Best Biotechnology Product" for the #PrixGalien USA Awards on November 7.    Congratulations to all the nominees, who share our deep commitment to innovative science.      We look forward to seeing you there! https://prn.to/3AzzxnO   

We believe how we work is just as important as the work we do. As part of our ongoing efforts to shape a “Work Better, Live Better” culture, we offer our colleagues a full range of mental health and well-being solutions through the Modern Health platform. This includes quick access to therapists, mental health and life coaches, and self-driven well-being programs and tools. In addition, colleagues and their eligible family members receive up to six free therapy sessions and six life-coaching sessions each year.     Learn more about working at BeiGene: https://bit.ly/3yQzp2l.    #MentalHealth #WorkplaceWellness #EmployeeWellbeing 

Our Q2 2024 earnings results are now available. Learn more about our commitment to making an impact for patients around the globe: https://lnkd.in/deXeqQSY

We’re honored to be receiving The Lymphoma Research Foundation’s 2024 Corporate Leadership Award! This award underscores our commitment to improving outcomes for patients with #lymphoma by advancing groundbreaking science and supporting the Foundation's research initiatives and education programs. We thank the Foundation for their ongoing partnership with BeiGene and for their dedication to supporting patients. Hear more from Dany Habr, M.D., our Head of Medical Affairs, North America & International Markets.     Learn more: https://bit.ly/4dxI8Wp.

In alignment with our commitment to advancing global health equity, we’re partnering with The Max Foundation to bring our innovative medicine to patients with chronic lymphocytic leukemia (#CLL) in low- and middle-income countries.       Last week, we were honored to welcome Pat Garcia-Gonzalez, CEO of The Max Foundation, Cathy Scheepers, Region Head for Africa at The Max Foundation, and Dr. Fisihatsion Tadesse, an Ethiopian hematologist. They joined Melika Davis, our Head of Global Clinical Operations, in a profound discussion on the challenges of CLL treatment in Ethiopia. Our collaboration with The Max Foundation stands as a crucial step in addressing the pressing needs of patients and clinics across the country.       Watch the video to learn more. #HealthEquity #PatientsFirst 

Javad Shahidi, SVP and Head of our Biotech Unit, recently joined other industry R&D leaders to discuss the evolving landscape of #oncology drug development, highlighting a key focus of ours – access to innovative medicines for more patients around the world.